

February 25, 2015



Testimony of Jody Daniels, GSK State Government Affairs  
Before Senate Health Care Committee in Support of SB 440

**GlaxoSmithKline**  
16863 Front Street NE  
Woodburn  
Oregon 97071  
Dir. 503 951 0693  
VMail 800 496 3772  
Ext. 80095  
[www.gsk.com](http://www.gsk.com)

Madame Chair and Members of the Committee:

GlaxoSmithKline strongly supports SB 440 and the State's pioneering efforts to move health care delivery from a system of payment for procedures, to payment for outcomes.

As we know, what gets measured gets done. Although GSK does not create outcome metrics, we have supported states across the country in their efforts to begin tracking key health outcomes measures in such areas as chronic disease management, prevention, immunization, and comprehensive medication management.

Our most recent work has been to partner with Governor Jay Inslee's Office in Washington State to set up and implement the first statewide Performance Measures Coordinating Committee (WPCC). The Committee is a diverse group of 29 stakeholders appointed by the Governor charged with developing an initial set of statewide health performance measures that will be reported and monitored annually for Medicaid managed care plans, public employee plans and soon, state exchange plans.

[http://www.hca.wa.gov/hw/Pages/performance\\_measures.aspx](http://www.hca.wa.gov/hw/Pages/performance_measures.aspx) The Washington committee adopted its first core set of measures this past January, after a 6-month and extensive process of review and collaboration. The final set includes 52 measures in key health care areas including immunizations, chronic disease, medication management and adherence, hospital readmissions and prevention. The criteria the WPCC used to select the final measures included: Is the metric a true outcome measure and widely used? Is it nationally vetted and recognized? Is it capable of moving the dial on improvements in health care delivery and population health?

There are two specific insights from the Washington process that I would like to share. First, the process benefited from having a diverse group of stakeholders at the table, and a very open process with opportunity for public comment. There was a great deal of interest in the initial measure set from patient advocacy groups, public health providers and consumers, and their input was valuable. Second, the committee struggled with the issue of selecting process measures, which are readily available through claims data, versus true outcome measures which require gathering some clinical data as well. It is the true outcome measures that are transformational, and SB 440 should make clear that this is the goal of the bill. While Oregon prides itself on doing things "The Oregon Way," the Washington example may be a good jumping off point.

GSK believes strongly in the triple aim of providing patient access to effective medication and treatment as a strategy for improving outcomes and lowering total health care cost. We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world. We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. GSK appreciates the opportunity to testify. We look forward to working within the public process to provide information on recognized health outcome measures in areas where our company has expertise. We welcome any questions or dialogue with the committee, staff or consultants. We believe Oregon's work in this area of outcome measures will be closely watched by other states and can serve as a national model.